Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huperzine A is a naturally occurring sesquiterpene alkaloid extracted from the Chinese club moss Huperzia serrata. It acts as a potent and reversible inhibitor of acetylcholinesterase in the central nervous system. By inhibiting this enzyme, it increases levels of acetylcholine—a neurotransmitter important for memory and learning—making it potentially beneficial for conditions characterized by cognitive decline such as Alzheimer’s disease and other dementias. Huperzine A may also interfere with beta-amyloid deposition pathways and inhibit N-methyl-D-aspartate (NMDA) receptors in the cerebral cortex. In China it is approved as a drug for Alzheimer’s disease; elsewhere it is marketed primarily as an herbal or dietary supplement[1][2][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Huperzine A.